Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × talquetamab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 27 Recurrence 4 Hematologic Neoplasms 2 Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1 Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 11 blinatumomab 8 fludarabine 7 venetoclax 6 fludarabine phosphate 5 Cytarabine 5 Rituximab 4 Lenalidomide 4 Dexamethasone 4 Blood Specimen Collection 4 Azacitidine 4 obinutuzumab 3 daratumumab 3 pembrolizumab 2 nilotinib 2 Vincristine 2 Radiotherapy 2 Methotrexate 2 Melphalan 2 Immunotherapy, Adoptive 2 Imatinib Mesylate 2 Idarubicin 2 Daunorubicin 2 Dasatinib 2 Chemotherapy, Adjuvant 2 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 thymoglobulin 1 tetrathiomolybdate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06993675 2025-08-29

ROTATE

Yale University

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡